Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
2.
Free Radic Biol Med ; 41(2): 213-21, 2006 Jul 15.
Article in English | MEDLINE | ID: mdl-16814101

ABSTRACT

Previous studies from this laboratory have demonstrated a critical role of cytosolic phospholipase A2 (cPLA2) and arachidonic acid in angiotensin II (Ang II) AT2 receptor-mediated signal transduction in renal epithelium. In primary proximal tubular epithelial cells exposed to hydrogen peroxide (H2O2), both the selective cPLA2 inhibitors and the cPLA2 antisense oligonucleotides significantly attenuated H2O2-induced arachidonic acid liberation and activation of p38(SAPK), ERK1/2, and Akt1. This H2O2-induced kinase activation was significantly attenuated by a Src kinase inhibitor PP2, or by transient transfection of carboxyl-terminal Src kinase (CSK) that maintained Src in the dormant form. Under basal conditions, Src coimmunoprecipitated with epidermal growth factor receptor (EGFR), while H2O2 increased EGFR phosphorylation in the complex. We observed that inhibition of EGFR kinase activity with AG1478 significantly attenuated H2O2-induced p38(SAPK) and ERK1/2 activation, but did not inhibit Akt1 activation. Furthermore, it seems that p38(SAPK) is upstream of ERK1/2 and Akt1, since a p38(SAPK) inhibitor SB203580 significantly blocked H2O2-induced activation of ERK1/2 and Akt1. Interestingly, overexpression of the dominant-negative p38(SAPK) isoform alpha inhibited ERK1/2 but not Akt1 activation. Our observations demonstrate that in these nontransformed cells, activation of cPLA2 is a converging point for oxidative stress and Ang II, which share common downstream signaling mechanisms including Src and EGFR. In addition, p38(SAPK) provides a positive input to both growth and antiapoptotic signaling pathways induced by acute oxidative stress.


Subject(s)
Cytosol/enzymology , Kidney/metabolism , Oxidative Stress , Phospholipases A/metabolism , Signal Transduction , p38 Mitogen-Activated Protein Kinases/metabolism , Base Sequence , DNA Primers , DNA, Complementary , Epithelium/metabolism , Phospholipases A2
3.
Kidney Int ; 67(5): 1731-8, 2005 May.
Article in English | MEDLINE | ID: mdl-15840019

ABSTRACT

BACKGROUND: The most striking feature of life is biodiversity. However, mechanisms of biodiversity remain poorly understood, as most protein orthologues of different species are highly homologous in sequence and identical in function. Interestingly, recent evidence has demonstrated heterogeneity for a G protein-coupled angiotensin II (Ang II) type 2 (AT(2)) receptor in both ligand binding and induction of arachidonic acid (AA) release. The present study investigated the properties of AT(2) receptors in closely related species. METHODS: AT(2) receptors cloned from human, rabbit, rat, and mouse were expressed in Chinese hamster ovary cells (CHO-K1), African green monkey kidney cells (COS-1), and human embryonic kidney (HEK)-293 cells and characterized in ligand binding and signal transductions. Critical residues in rabbit AT(2) receptor attributable to heterogeneity were examined using both gain-of-function and loss-of-function approaches with mutagenesis. RESULTS: The newly cloned rabbit AT(2) receptor exhibits distinct biochemical and biologic properties compared to its highly homologous orthologues (91% in overall amino acid sequence) of rat, mouse, and human. All these orthologues activate SH2 domain-containing phosphatase-1 (SHP-1) and show similar binding affinities for Ang II and AT(2)-specific ligands CGP42112A and PD123319. However, reducing agent dithiothreitol (DTT) inactivates the rabbit orthologue but potentiates the others in ligand binding, a hallmark of AT(2) versus AT(1) receptor subtypes. Most interestingly, rabbit AT(2) receptor, but not the other orthologues, induces AA release in various cell systems when stimulated by both Ang II and CGP42112A, the peptide antagonist. Mutagenesis studies and sequence analyses further indicate that residues His(106), Asp(188), and Thr(293) are responsible for the DTT inactivation and residues Val(209) and Val(249) are partially responsible for AA release. CONCLUSION: These results deny the coexistence of an additional AT(2) subtype in rabbit proximal tubule cells and demonstrate for the first time the presence of functional diversity for closely related Eutherian orthologues of a G protein-coupled receptor (GPCR) that are more than 90% homologous in the amino acid sequence.


Subject(s)
Receptor, Angiotensin, Type 2/metabolism , Amino Acid Sequence , Amino Acid Substitution , Animals , Arachidonic Acid/metabolism , Base Sequence , Binding Sites/genetics , CHO Cells , COS Cells , Cell Line , Chlorocebus aethiops , Cloning, Molecular , Cricetinae , DNA, Complementary/genetics , Dithiothreitol/pharmacology , Humans , Intracellular Signaling Peptides and Proteins , Kinetics , Ligands , Mice , Molecular Sequence Data , Mutagenesis, Site-Directed , Phosphorylation , Protein Phosphatase 1 , Protein Tyrosine Phosphatase, Non-Receptor Type 6 , Protein Tyrosine Phosphatases/metabolism , Rabbits , Rats , Receptor, Angiotensin, Type 2/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Homology, Amino Acid , Species Specificity
4.
Am J Cardiovasc Drugs ; 5(1): 1-6, 2005.
Article in English | MEDLINE | ID: mdl-15631532

ABSTRACT

African Americans represent a population with the highest prevalence of hypertension in the world, associated with earlier onset, more severity, poorer control rates, and more cardiovascular and renal complications than White Americans. The high prevalence of type 2 diabetes mellitus in African Americans, compared with Whites, compounds the excessive burden of cardiovascular and kidney disease. The Hypertension in African American Working Group of the International Society of Hypertension in Blacks recently developed a consensus document that presented a practical, evidence-based approach aimed at achieving better blood pressure control. It was thought that a new approach, targeted at US Blacks, was needed to achieve better blood pressure control and enhanced target tissue protection. Key elements of the document include (i) emphasis on the importance of therapeutic lifestyle modification such as weight loss, decreased sodium ingestion, increased potassium intake, exercise, and weight loss, to name a few; (ii) recommendation of combination antihypertensive agents because of the high prevalence of individuals with >15 mm Hg above SBP goal and/or 10 mmHg above DBP goal (140/90 unless there is also diabetes and/or kidney disease with >1 g proteinuria daily). Effective combinations include beta-adrenoceptor antagonist/diuretic, ACE inhibitor/diuretic, ACE inhibitor/calcium channel antagonist, and angiotensin receptor antagonist/diuretic; and (iii) the recommendations do not differ from other racial/ethnic groups where specific or compelling indications for the use of specific classes of antihypertensive agents exist.


Subject(s)
Black or African American , Hypertension/therapy , Practice Guidelines as Topic , Antihypertensive Agents/therapeutic use , Blood Pressure Determination/standards , Humans , Hypertension/epidemiology , Life Style
5.
J Am Coll Cardiol ; 43(6): 1047-55, 2004 Mar 17.
Article in English | MEDLINE | ID: mdl-15028365

ABSTRACT

OBJECTIVES: We report on a subanalysis of the effects of losartan and atenolol on cardiovascular events in black patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. BACKGROUND: The LIFE study compared losartan-based to atenolol-based therapy in 9,193 hypertensive patients with left ventricular hypertrophy (LVH). Overall, the risk of the primary composite end point (cardiovascular death, stroke, myocardial infarction) was reduced by 13% (p = 0.021) with losartan, with similar blood pressure (BP) reduction in both treatment groups. There was a suggestion of interaction between ethnic background and treatment (p = 0.057). METHODS: Exploratory analyses were performed that placed LIFE study patients into black (n = 533) and non-black (n = 8,660) categories, overall, and in the U.S. (African American [n = 523]; non-black [n = 1,184]). RESULTS: A significant interaction existed between the dichotomized groups (black/non-black) and treatment (p = 0.005); a test for qualitative interaction was also significant (p = 0.016). The hazard ratio (losartan relative to atenolol) for the primary end point favored atenolol in black patients (1.666 [95% confidence interval (CI) 1.043 to 2.661]; p = 0.033) and favored losartan in non-blacks (0.829 [95% CI 0.733 to 0.938]; p = 0.003). In black patients, BP reduction was similar in both groups, and regression of electrocardiographic-LVH was greater with losartan. CONCLUSIONS: Results of the subanalysis are sufficient to generate the hypothesis that black patients with hypertension and LVH might not respond as favorably to losartan-based treatment as non-black patients with respect to cardiovascular outcomes, and do not support a recommendation for losartan as a first-line treatment for this purpose. The subanalysis is limited by the relatively small number of events.


Subject(s)
Antihypertensive Agents/therapeutic use , Atenolol/therapeutic use , Hypertension/prevention & control , Hypertrophy, Left Ventricular/complications , Losartan/therapeutic use , Aged , Aged, 80 and over , Antihypertensive Agents/administration & dosage , Asian People , Atenolol/administration & dosage , Black People , Blood Pressure/drug effects , Drug Therapy, Combination , Europe , Female , Humans , Hypertension/complications , Hypertension/genetics , Hypertension/mortality , Losartan/administration & dosage , Male , Middle Aged , Treatment Outcome , United States , White People
6.
In Vitro Cell Dev Biol Anim ; 40(1-2): 22-34, 2004.
Article in English | MEDLINE | ID: mdl-14748622

ABSTRACT

Human proximal tubule epithelial cell lines are potentially useful models to elucidate the complex cellular and molecular details of water and electrolyte homeostasis in the kidney. Samples of normal adult human kidney tissue were obtained from surgical specimens, and S1 segments of proximal convoluted tubules were microdissected, placed on collagen-coated culture plate inserts, and cocultured with lethally irradiated 3T3 fibroblasts. Primary cultures of proximal tubule epithelial cells were infected with a replication-defective retroviral construct encoding either wild-type or temperature-sensitive simian virus 40 large T-antigen. Cells forming electrically resistive monolayers were selected and expanded in culture. Three cell lines (HPCT-03-ts, HPCT-05-wt, and HPCT-06-wt) were characterized for proximal tubule phenotype by electron microscopy, electrophysiology, immunofluorescence, Southern hybridization, and reverse transcriptase-polymerase chain reaction. Each of the three formed polarized, resistive epithelial monolayers with apical microvilli, tight junctional complexes, numerous mitochondria, well-developed Golgi complexes, extensive endoplasmic reticulum, convolutions of the basolateral plasma membrane, and a primary cilium. Each exhibited succinate, phosphate, and Na,K- adenosine triphosphatase (ATPase) transport activity, as well as acidic dipeptide- and adenosine triphosphate-regulated mechanisms of ion transport. Transcripts for Na(+)-bicarbonate cotransporter, Na(+)-H(+) exchanger isoform 3, Na,K-ATPase, parathyroid hormone receptor, epidermal growth factor receptor, and vasopressin V2 receptor were identified. Furthermore, immunoreactive sodium phosphate cotransporter type II, vasopressin receptor V1a, and CLIC-1 (NCC27) were also identified. These well-differentiated, transport-competent cell lines demonstrated the growth, immortalization, and differentiation potential of normal, adult, human proximal tubule cells and consequently have wide applicability in cell biology and renal physiology.


Subject(s)
Cell Differentiation , Cell Line , Cell Proliferation , Epithelial Cells/cytology , Epithelial Cells/physiology , Kidney Tubules, Proximal/cytology , Animals , Biological Transport , Biomarkers , Cell Polarity , Cells, Cultured , Coculture Techniques , Fibroblasts/cytology , Fibroblasts/metabolism , Humans , Ions/metabolism , Kidney Tubules, Proximal/metabolism , Membrane Proteins/metabolism , Microscopy, Electron, Transmission , Phenotype , Retroviridae/genetics , Retroviridae/metabolism
7.
Kidney Int ; 65(2): 551-63, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14717925

ABSTRACT

BACKGROUND: Recent evidence from this laboratory have demonstrated a critical role of phospholipase A2 (PLA2) and arachidonic acid in angiotensin II type 2 (AT2) receptor-mediated kinase activation in renal epithelium independent of phosphoinositide- specific phospholipase C (PLC) and without the necessity of eicosanoid biosynthesis. In the present study, we investigated whether cyclic stress phosphorylates and activates the mitogen-activated protein kinase (MAPK) pathway and whether PLA2 activation mediates mechanotransduction in renal epithelial cells. The rational for studying kidney epithelial cells relates to their similarity to podocytes, which undergo mechanical stretch related to changes in intraglomerular pressure. METHODS: To produce strain or stretch, primary cultures of rabbit proximal tubular cell cells are grown in tissue culture wells having a collagen-coated Silastic deformable membrane bottoms and applying vacuum to the well to generate alternating cycles of stretch and relaxation (30 cycles/min). RESULTS: We found that cyclic stretching of rabbit proximal tubular cells caused a time- and intensity-dependent activation of extracellular signal-regulated kinases 1 and 2 (ERK 1/2) in proximal tubular cells as detected by its phosphorylation. In addition, mechanical stretch induced PLA2 activation and a subsequent rapid release of arachidonic acid. Inhibition of PLA2 by mepacrine and methyl arachidonyl fluorophosphonate ketone (AACOCF3) attenuated both arachidonic acid release and ERK 1/2 activation by cyclic stretch, supporting the importance of PLA2 as a mediator of mechanotransduction in renal proximal tubular cells. A requirement for extracellular Ca2+ and stretch-activated Ca2+ channels was also documented. Complete inhibition of ERK 1/2 by PD98059, a MAPK kinase (MEK) inhibitor, did not suppress stretch- induced PLA2 activation and arachidonic acid release, suggesting the later events were upstream of ERK 1/2. Cyclic stretch also caused rapid phosphorylation of the EGF receptor kinase and c-Src. Furthermore, arachidonic acid itself induced time- and dose-dependent phosphorylation of c-Src. In addition, the c-Src inhibitor PP2 and selective EGF receptor kinase inhibitor AG1478 attenuated both ERK 1/2 and EGF receptor phosphorylation by cyclic stretch. CONCLUSION: PLA2 dependence for ERK 1/2 activation in response to cyclic stretch in proximal tubular epithelial cells was established in this report. In addition, these findings indicate cyclic stretch increased the tyrosine phosphorylation of the EGF receptor and c-Src and that c-Src acts upstream of the EGF receptor to mediate its phosphorylation, whereby both are critical for stretch- induced ERK 1/2 activation in rabbit proximal tubular cells. These observations documents for the first time a mechanism of mechanical stretch-induced kinase activation mediated by stretch activated Ca2+ channels and PLA2-dependent release of arachidonic acid.


Subject(s)
Kidney Tubules, Proximal/enzymology , MAP Kinase Signaling System/physiology , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/metabolism , Phospholipases A/metabolism , Animals , Arachidonic Acid/metabolism , Calcium/metabolism , Calcium Channels/metabolism , Cells, Cultured , ErbB Receptors/metabolism , Kidney Tubules, Proximal/cytology , Male , Mitogen-Activated Protein Kinase 3 , Phospholipases A2 , Rabbits , Stress, Mechanical , Tritium , src-Family Kinases/metabolism
8.
Hypertension ; 42(6): 1087-92, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14610097

ABSTRACT

Salt sensitivity (SS) has been linked to human hypertension. We examined ethnic differences in the relation between SS; erythrocyte sodium (Na+i), calcium (Ca2+i), potassium (K+i), and magnesium (Mg2+i); and sodium pump activity in African-American (AA) and white women. In a crossover protocol, similar numbers of normotensive, hypertensive, AA, and white women were randomized to 7 days of a 20 meq/d and a >200 meq/d salt diet (n=199). After an overnight inpatient stay, group differences in supine blood pressure (BP), heart rate, erythrocyte cations, and sodium pump activity were measured. The prevalence of SS (53.5% vs 51%) and salt resistance (26.3% vs 30.0%) was similar in both races. Greater mean BP increase with salt loading was seen in AA vs white hypertensives but not between the normotensive women. In hypertensives, increase in mean arterial pressure was 12.6 vs 8.2 mm Hg in AAs vs whites, respectively (P<0.01), and for systolic BP, it was 23 vs 14.8 mm Hg (P<0.01). Higher Na+i and Ca2+i were noted in SS and salt-intermediate AA than in the corresponding white subjects. Na+i, Ca2+i, and the ratios of Na+i to K+i and of Ca2+i to Mg2+i were positively correlated with salt responsiveness in AA but not in white women. Sodium pump activity was similar between groups, although the change in maximal activity trended to vary inversely with SS in AA. In closely matched AA and white women, the prevalence of SS is similarly high in both races, although the magnitude of BP increase is greater in AA hypertensives. In AA but not in whites, SS is positively associated with Na+i, Ca2+i, and the ratios of Na+i to K+i and of Ca2+i to Mg2+i.


Subject(s)
Black People , Hypertension/ethnology , Sodium, Dietary/pharmacology , White People , Blood Pressure/drug effects , Cations/metabolism , Cross-Over Studies , Erythrocytes/metabolism , Female , Humans , Hypertension/metabolism , Hypertension/physiopathology , Middle Aged , Postmenopause , Sodium/metabolism , Sodium-Potassium-Exchanging ATPase/metabolism
9.
Kidney Int Suppl ; (83): S74-6, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12864879

ABSTRACT

An interim analysis of the AASK trial at three years demonstrates a renoprotective effect [slower decline in glomerular filtration rate (GFR), delayed onset of significant decrease in GFR, end-stage renal disease (ESRD) or death, and a decrease in urinary protein excretion] of the angiotensin converting enzyme (ACE) inhibitor, ramipril, as compared to the dihydropyridine calcium channel blocker (DHP-CCB), amlodipine, in patients with mild-to-moderate renal insufficiency. The beneficial effect occurred in the presence of similar levels of blood pressure control and was apparent in patients with proteinuric (beyond the threshold of "dipstick positive" proteinuria, 300 mg/day) and non-proteinuric hypertensive nephrosclerosis. At the time of the interim analysis, the effectiveness of the beta-blocker metoprolol was not significantly different from that of the ACE inhibitor. The data suggest that DHP-CCBs should be used with caution in the presence of mild-to-moderate renal insufficiency.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Black or African American , Hypertension, Renal/drug therapy , Nephrosclerosis/diet therapy , Ramipril/therapeutic use , Renal Insufficiency/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Amlodipine/therapeutic use , Calcium Channel Blockers/therapeutic use , Glomerular Filtration Rate/drug effects , Humans , Hypertension, Renal/ethnology , Metoprolol/therapeutic use , Nephrosclerosis/ethnology , Renal Insufficiency/ethnology
10.
J Am Soc Nephrol ; 14(7 Suppl 2): S166-72, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12819323

ABSTRACT

Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African Americans with hypertensive kidney disease who receive recommended anti-hypertensive therapy. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects of three medications used as initial anti-hypertensive therapy (ramipril, metoprolol, and amlodipine) and two levels of BP control. Of the 1094 trial participants, approximately 650 to 700 individuals who have not reached ESRD will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socioeconomic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression: treatment of hypertension and use of renoprotective, anti-hypertensive medication. The minimum duration of follow-up in the Cohort Study is 5 yr (total of 9 to 12 yr, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.


Subject(s)
Black or African American/statistics & numerical data , Hypertension/epidemiology , Kidney Failure, Chronic/epidemiology , Adolescent , Adult , Age Distribution , Aged , Antihypertensive Agents/therapeutic use , Cohort Studies , Drug Therapy, Combination , Female , Humans , Hypertension/diagnosis , Hypertension/drug therapy , Incidence , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/therapy , Male , Middle Aged , Prognosis , Randomized Controlled Trials as Topic , Research Design , Risk Assessment , Sex Distribution , Survival Rate , United States
12.
Postgrad Med ; 112(4): 51-2, 55, 59-62 passim, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12400149

ABSTRACT

Outdated and biased attitudes and care standards impede optimal care of hypertension in African Americans. The negative expectations that blood pressure targets cannot be reached must be overcome by systematic and appropriate education and treatment. However, physicians should expect that (1) African American patients with elevated blood pressure benefit from early and intensive management, (2) blood pressure can be maintained at goal with appropriate therapeutic lifestyle changes and medications, and (3) complications related to high blood pressure can be avoided. To bring blood pressure down to the target goal, combination pharmacologic therapy is often required. When extensive efforts to achieve blood pressure control prove unattainable in the primary care setting, consultation with a hypertension specialist should be considered.


Subject(s)
Black or African American/education , Black or African American/psychology , Hypertension/ethnology , Hypertension/prevention & control , Black or African American/statistics & numerical data , Antihypertensive Agents/adverse effects , Attitude of Health Personnel , Diet/adverse effects , Exercise , Goals , Health Knowledge, Attitudes, Practice , Health Priorities , Health Services Accessibility/standards , Humans , Hypertension/diagnosis , Life Style , Patient Compliance/ethnology , Physician's Role , Prejudice , Primary Health Care/methods , Primary Health Care/standards , Quality of Health Care , Risk Factors , Socioeconomic Factors , United States/epidemiology
13.
Postgrad Med ; 112(4): 73-4, 77-80, 83-4, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12400150

ABSTRACT

Treatment of hypertension in African Americans has special challenges, including a lack of objective trial data on which to base decisions and differing benefits and responses than with other patients. However, adequate control is possible and should be the goal of treating physicians. This article describes current "best practice" guidance on appropriate treatment of high blood pressure in African Americans. Two patient scenarios offer insight into clinical strategies.


Subject(s)
Black or African American/psychology , Hypertension/ethnology , Hypertension/prevention & control , Patient Care Planning , Practice Guidelines as Topic , Primary Health Care/methods , Adrenergic beta-Antagonists/therapeutic use , Black or African American/education , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antihypertensive Agents/therapeutic use , Benchmarking , Blood Pressure , Calcium Channel Blockers/therapeutic use , Diet, Sodium-Restricted , Diuretics/therapeutic use , Evidence-Based Medicine , Goals , Humans , Hypertension/etiology , Life Style , Male , Middle Aged , Patient Care Planning/standards , Primary Health Care/standards , Risk Assessment , Risk Factors
14.
Postgrad Med ; 112(4): 24-6, 29-30, 33-4 passim, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12405099

ABSTRACT

African Americans have a higher prevalence of hypertension, diabetes, cardiovascular disease (CVD), stroke, and renal disease than white Americans. The high rates of diabetes and hypertension in children and of type 2 diabetes, stroke, and CVD in women are particularly striking. In this article, Drs Sowers, Ferdinand, Bakris, and Douglas examine the biologic, social, and genetic factors that contribute to these health disparities, the risk for which appears in early childhood.


Subject(s)
Black People/genetics , Hypertension/epidemiology , Hypertension/etiology , Black or African American/statistics & numerical data , Age Distribution , Cardiovascular Diseases/complications , Cardiovascular Diseases/epidemiology , Cause of Death , Comorbidity , Diabetes Complications , Diabetes Mellitus/epidemiology , Female , Humans , Kidney Diseases/complications , Kidney Diseases/epidemiology , Male , Obesity/complications , Obesity/epidemiology , Population Surveillance , Prevalence , Residence Characteristics/statistics & numerical data , Risk Factors , Sex Distribution , Smoking/adverse effects , Smoking/epidemiology , Socioeconomic Factors , Stroke/complications , Stroke/epidemiology , United States/epidemiology
15.
Proc Natl Acad Sci U S A ; 99(19): 12049-54, 2002 Sep 17.
Article in English | MEDLINE | ID: mdl-12221292

ABSTRACT

Conventional mode of activation of SH2 domain-containing phosphatase 1 (SHP-1) by a single transmembrane (TM) inhibitory receptor such as killer cell inhibitory receptor, Fcgamma receptor type IIb1, and paired Ig-like receptors of inhibitory types requires tyrosine phosphorylation of immunoreceptor tyrosine-based inhibitory (ITIM) motifs in the cytoplasmic domains of the inhibitory receptors. Contrary to this paradigm, AT(2), a G protein-coupled 7TM receptor that does not undergo tyrosine phosphorylation in response to angiotensin II (Ang II) stimulation, also activates SHP-1. Here we show that SHP-1 constitutively and physically associates with AT(2) receptor in transfected COS-7 cells. On stimulation by Ang II, SHP-1 becomes activated and dissociated from AT(2) receptor, independent of pertussis toxin. Cotransfection of transducin G(betagamma) inhibits SHP-1/AT(2) association and the SHP-1 activation, whereas cotransfection of C-terminal of beta-adrenergic receptor kinase, which abrogates G(betagamma) signaling, facilitates SHP-1 activation. Surprisingly, SHP-1/AT(2) association and the SHP-1 activation requires the presence of G(alphas) as shown by differential coimmunoprecipitation, dominant negative G(alphas), constitutively active G(alphas), and G(alpha) peptides. A mutant AT(2) receptor D141A-R142L that is inactive in G(alpha) protein activation constitutively associates with SHP-1 and activates it. Together, these results indicate that G(alphas) alone, rather than exclusively in the form of G(alphabetagamma) heterotrimer may facilitate signal transduction for G protein-coupled receptors, suggesting a novel mechanism distinct from the classic paradigm of heterotrimeric G proteins. The AT(2)-mediated ITIM-independent activation of SHP-1 that is distinct from the conventional mode of activation, may represent a general paradigm for activation of SHP-1/2-class tyrosine phosphatases by G protein-coupled receptors.


Subject(s)
GTP-Binding Protein beta Subunits , GTP-Binding Protein gamma Subunits , Heterotrimeric GTP-Binding Proteins/metabolism , Protein Tyrosine Phosphatases/metabolism , Receptors, Angiotensin/metabolism , Amino Acid Sequence , Animals , CHO Cells , COS Cells , Cricetinae , Cyclic AMP-Dependent Protein Kinases/genetics , Cyclic AMP-Dependent Protein Kinases/metabolism , Enzyme Activation , Heterotrimeric GTP-Binding Proteins/genetics , In Vitro Techniques , Intracellular Signaling Peptides and Proteins , Mutation , Protein Phosphatase 1 , Protein Structure, Tertiary , Protein Tyrosine Phosphatase, Non-Receptor Type 6 , Protein Tyrosine Phosphatases/genetics , Rats , Receptor, Angiotensin, Type 2 , Receptors, Angiotensin/chemistry , Receptors, Angiotensin/genetics , Receptors, Cell Surface/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Signal Transduction , Transfection , beta-Adrenergic Receptor Kinases
16.
Arch Intern Med ; 162(14): 1636-43, 2002 Jul 22.
Article in English | MEDLINE | ID: mdl-12123409

ABSTRACT

BACKGROUND: The African American Study of Kidney Disease and Hypertension (AASK) is an ongoing trial to evaluate the effect of blood pressure and choice of antihypertensive drug on the rate of decline of renal function. OBJECTIVE: To present the success of the AASK in achieving the trial's rigorous blood pressure goals in an extremely challenging patient population. METHODS: The AASK participants included African American patients with hypertension (n = 1094), aged 18 to 70 years, with glomerular filtration rates between 20 and 65 mL/min per 1.73 m(2) and no other identified causes of renal insufficiency. Participants were randomized to a goal mean arterial blood pressure (MAP) of either 102 to 107 mm Hg (usual MAP goal) or 92 mm Hg or less (low MAP goal). Participants in each of these groups were also randomized (double-blind) to a regimen containing metoprolol succinate, ramipril, or amlodipine besylate. Additional agents were added, if required, in the following recommended order: furosemide, doxazosin mesylate, clonidine hydrochloride, or hydralazine hydrochloride (or minoxidil, if needed). RESULTS: In participants randomized to the low MAP goal, the percentage of participants who achieved a blood pressure of less than 140/90 mm Hg increased from a baseline of 20.0% to 78.9% by 14 months after randomization. For usual MAP goal participants, the corresponding percentages increased from 21.5% to 41.8%. The difference in median levels of MAP between the 2 MAP goal groups increased and remained at approximately 12 mm Hg. Blood pressure reduction was similar regardless of age, sex, body mass index, education, insurance or employment status, income, or marital status. CONCLUSION: The blood pressure goals set and achieved in AASK participants clearly demonstrate that adequate blood pressure control can be achieved even in hypertensive populations whose blood pressure is the most difficult to control.


Subject(s)
Black People , Blood Pressure/physiology , Hypertension/complications , Hypertension/physiopathology , Kidney Diseases/complications , Kidney Diseases/physiopathology , Adolescent , Adult , Aged , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Cohort Studies , Double-Blind Method , Female , Follow-Up Studies , Glomerular Filtration Rate/drug effects , Glomerular Filtration Rate/physiology , Humans , Hypertension/drug therapy , Kidney Diseases/drug therapy , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...